Biophan Announces Online Slide Presentation on Impacts of Nanotechnology on Future of Medical Devices and Biomaterials; CEO Michael Weiner Presented Company's Proprietary Solutions at Cientifica World NanoEconomic Forum in Dublin, Ireland.

ROCHESTER, N.Y. -- Biophan Technologies, Inc. (OTCBB:BIPH), a developer of next-generation biomedical technology, has announced the online availability of a slide presentation by CEO Michael Weiner, outlining his views on the potential that nanotechnology will have on the future of biomedical devices and biomaterials. The presentation includes a review of Biophan's nanotechnology applications in a range of emerging multi-billion-dollar markets for biosciences and health care.

Mr. Weiner included the slide presentation in an address to a gathering of leading researchers and industry innovators attending the World Nano-Economic Congress on April 20-21, in Dublin, Ireland. Other presenters included representatives from Siemens, NEC, DSM, and Advance Nanotechnology. Biophan and its licensors currently hold 114 patents, licenses, and applications. Many of them are in areas of applied nanotechnology for the biomedical marketplace, representing one of the industry's most formidable intellectual property portfolios in several emerging markets.

The presentation outlines some of the Company's nano-based technologies, such as nanomagnetic particle coatings and resonant circuits that make stents and other hard-to-image devices imageable in Magnetic Resonance Imaging (MRI) systems. Applications of this technology in the $5 billion stent marketplace are designed to provide physicians with a range of advantages, including safer and more effective imaging options beyond X-ray and fluoroscopy, to clearly view inside implanted vascular stents to determine post-operative arterial health and device effectiveness. Biophan is developing other nanotechnology solutions including a battery powered by body heat, jointly being developed with NASA.

The presentation includes descriptions of research and development in Biophan's Nanolution division to create next-generation systems and products for the projected $40 billion drug-delivery marketplace. Several of Biophan's advanced drug-eluting coating technologies for stents and other implantable devices are outlined, including applications to allow on-demand surface elution for improved control over the drug-elution treatment, reloadable drug-eluting coatings that can be refreshed with new medicines for longer therapeutic courses, and guided drug delivery to target tumors or other specific sites.

Biophan invites all interested parties and investors to download and view the presentation by visiting http://www.tril02.com/biph/biph-wnec.ppt 

About Biophan Technologies

Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers and interventional surgical devices such as catheters, guidewires, stents, and other implants to allow them to be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 114 U.S. patents, licenses, or applications. This total includes 36 issued U.S. patents, 6 recently-allowed applications that will issue as patents in the near future, and 72 pending applications at various stages of examination at the U.S. Patent and Trademark Office, plus international applications. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE:BSX - News) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.